@article{StojanovićFuchsFiedleretal.2020,
  author    = {Stojanović, Stevan D. and Fuchs, Maximilian and Fiedler, Jan and Xiao, Ke and Meinecke, Anna and Just, Annette and Pich, Andreas and Thum, Thomas and Kunz, Meik},
  title     = {Comprehensive bioinformatics identifies key microRNA players in ATG7-deficient lung fibroblasts},
  series = {International Journal of Molecular Sciences},
  volume    = {21},
  journal   = {International Journal of Molecular Sciences},
  number    = {11},
  issn      = {1422-0067},
  doi       = {10.3390/ijms21114126},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-285181},
  year      = {2020},
  abstract  = {Background: Deficient autophagy has been recently implicated as a driver of pulmonary fibrosis, yet bioinformatics approaches to study this cellular process are lacking. Autophagy-related 5 and 7 (ATG5/ATG7) are critical elements of macro-autophagy. However, an alternative ATG5/ATG7-independent macro-autophagy pathway was recently discovered, its regulation being unknown. Using a bioinformatics proteome profiling analysis of ATG7-deficient human fibroblasts, we aimed to identify key microRNA (miR) regulators in autophagy. Method: We have generated ATG7-knockout MRC-5 fibroblasts and performed mass spectrometry to generate a large-scale proteomics dataset. We further quantified the interactions between various proteins combining bioinformatics molecular network reconstruction and functional enrichment analysis. The predicted key regulatory miRs were validated via quantitative polymerase chain reaction. Results: The functional enrichment analysis of the 26 deregulated proteins showed decreased cellular trafficking, increased mitophagy and senescence as the major overarching processes in ATG7-deficient lung fibroblasts. The 26 proteins reconstitute a protein interactome of 46 nodes and miR-regulated interactome of 834 nodes. The miR network shows three functional cluster modules around miR-16-5p, miR-17-5p and let-7a-5p related to multiple deregulated proteins. Confirming these results in a biological setting, serially passaged wild-type and autophagy-deficient fibroblasts displayed senescence-dependent expression profiles of miR-16-5p and miR-17-5p. Conclusions: We have developed a bioinformatics proteome profiling approach that successfully identifies biologically relevant miR regulators from a proteomics dataset of the ATG-7-deficient milieu in lung fibroblasts, and thus may be used to elucidate key molecular players in complex fibrotic pathological processes. The approach is not limited to a specific cell-type and disease, thus highlighting its high relevance in proteome and non-coding RNA research.},
  language  = {en}
}
@article{JazbutyteStumpnerRedeletal.2012,
  author    = {Jazbutyte, Virginija and Stumpner, Jan and Redel, Andreas and Lorenzen, Johan M. and Roewer, Norbert and Thum, Thomas and Kehl, Franz},
  title     = {Aromatase Inhibition Attenuates Desflurane-Induced Preconditioning against Acute Myocardial Infarction in Male Mouse Heart In Vivo},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-151258},
  pages     = {e42032},
  year      = {2012},
  abstract  = {The volatile anesthetic desflurane (DES) effectively reduces cardiac infarct size following experimental ischemia/reperfusion injury in the mouse heart. We hypothesized that endogenous estrogens play a role as mediators of desflurane-induced preconditioning against myocardial infarction. In this study, we tested the hypothesis that desflurane effects local estrogen synthesis by modulating enzyme aromatase expression and activity in the mouse heart. Aromatase metabolizes testosterone to 17b- estradiol (E2) and thereby significantly contributes to local estrogen synthesis. We tested aromatase effects in acute myocardial infarction model in male mice. The animals were randomized and subjected to four groups which were pre-treated with the selective aromatase inhibitor anastrozole (A group) and DES alone (DES group) or in combination (A+DES group) for 15 minutes prior to surgical intervention whereas the control group received 0.9\% NaCl (CON group). All animals were subjected to 45 minutes ischemia following 180 minutes reperfusion. Anastrozole blocked DES induced preconditioning and increased infarct size compared to DES alone (37.94615.5\% vs. 17.163.62\%) without affecting area at risk and systemic hemodynamic parameters following ischemia/reperfusion. Protein localization studies revealed that aromatase was abundant in the murine cardiovascular system with the highest expression levels in endothelial and smooth muscle cells. Desflurane application at pharmacological concentrations efficiently upregulated aromatase expression in vivo and in vitro. We conclude that desflurane efficiently regulates aromatase expression and activity which might lead to increased local estrogen synthesis and thus preserve cellular integrity and reduce cardiac damage in an acute myocardial infarction model.},
  language  = {en}
}
@article{JazbutyteFiedlerKneitzetal.2012,
  author    = {Jazbutyte, Virginija and Fiedler, Jan and Kneitz, Susanne and Galuppo, Paolo and Just, Annette and Holzmann, Angelika and Bauersachs, Johann and Thum, Thomas},
  title     = {MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart},
  series = {AGE},
  volume    = {35},
  journal   = {AGE},
  number    = {3},
  doi       = {10.1007/s11357-012-9407-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126745},
  pages     = {747-762},
  year      = {2012},
  abstract  = {MicroRNAs (miRs) are small non- coding RNA molecules controlling a plethora of biological processes such as development, cellular survival and senescence. We here determined miRs differentially regulated during cardiac postnatal development and aging. Cardiac function, morphology and miR expression profiles were determined in neonatal, 4 weeks, 6 months and 19 months old normotensive male healthy C57/Bl6N mice. MiR-22 was most prominently upregulated during cardiac aging. Cardiac expression of its bioinformatically predicted target mimecan (osteoglycin, OGN) was gradually decreased with advanced age. Luciferase reporter assays validated mimecan as a bona fide miR-22 target. Both, miR-22 and its target mimecan were co- expressed in cardiac fibroblasts and smooth muscle cells. Functionally, miR-22 overexpression induced cellular senescence and promoted migratory activity of cardiac fibroblasts. Small interference RNA-mediated silencing of mimecan in cardiac fibroblasts mimicked the miR-22-mediated effects. Rescue experiments revealed that the effects of miR-22 on cardiac fibroblasts were only partially mediated by mimecan. In conclusion, miR-22 upregulation in the aging heart contributed at least partly to accelerated cardiac fibroblast senescence and increased migratory activity. Our results suggest an involvement of miR-22 in age-associated cardiac changes, such as cardiac fibrosis.},
  language  = {en}
}
@article{FrantzFalcaoPiresBalligandetal.2018,
  author    = {Frantz, Stefan and Falcao-Pires, Ines and Balligand, Jean-Luc and Bauersachs, Johann and Brutsaert, Dirk and Ciccarelli, Michele and Dawson, Dana and de Windt, Leon J. and Giacca, Mauro and Hamdani, Nazha and Hilfiker-Kleiner, Denise and Hirsch, Emilio and Leite-Moreira, Adelino and Mayr, Manuel and Thum, Thomas and Tocchetti, Carlo G. and van der Velden, Jolanda and Varricchi, Gilda and Heymans, Stephane},
  title     = {The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC},
  series = {European Journal of Heart Failure},
  volume    = {20},
  journal   = {European Journal of Heart Failure},
  doi       = {10.1002/ejhf.1138},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229091},
  pages     = {445-459},
  year      = {2018},
  abstract  = {Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.},
  language  = {en}
}
@article{deBoerDeKeulenaerBauersachsetal.2019,
  author    = {de Boer, Rudolf A. and De Keulenaer, Gilles and Bauersachs, Johann and Brutsaert, Dirk and Cleland, John G. and Diez, Javier and Du, Xiao-Jun and Ford, Paul and Heinzel, Frank R. and Lipson, Kenneth E. and McDonagh, Theresa and Lopez-Andres, Natalia and Lunde, Ida G. and Lyon, Alexander R. and Pollesello, Piero and Prasad, Sanjay K. and Tocchetti, Carlo G. and Mayr, Manuel and Sluijter, Joost P. G. and Thum, Thomas and Tsch{\"o}pe, Carsten and Zannad, Faiez and Zimmermann, Wolfram-Hubertus and Ruschitzka, Frank and Filippatos, Gerasimos and Lindsey, Merry L. and Maack, Christoph and Heymans, Stephane},
  title     = {Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology},
  series = {European Journal of Heart Failure},
  volume    = {21},
  journal   = {European Journal of Heart Failure},
  doi       = {10.1002/ejhf.1406},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223613},
  pages     = {272-285},
  year      = {2019},
  abstract  = {Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.},
  language  = {en}
}